The acquisition will allow Kiadis to offer clients services in isolating bioactive molecules from complex mixtures, as well as carry out advanced chemical synthesis and lead optimisation in house. Selact , which has focused on building up a position in the area of difficult-to-synthesize molecules, chiral synthesis, chiral catalysis and analytical support, will operate as a wholly owned subsidiary of Kiadis.
The combined company has additional resources and sufficient cash reserves to continue to progress and expand on Kiadis high-resolution screening.
Gerard Dijkstra, Kiadis ' CEO, said the acquisition would allow the company's clients "to access first class molecular chemistry, a sine qua non for drug discovery and development."
Financial terms of the acquisition have not been disclosed.